This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Calendar: Key Clinical Trial Dates

Company: Oxigene (OXGN)
Drug/indication: Zybrestat for non-small cell lung cancer
Clinical trial event: Phase II results
Timing: 2009

The phase II study adds Zybrestat to a standard first-line regimen for lung cancer for Avastin and chemotherapy. The study enrolled 60 patients and is using progression-free survival as the primary endpoint.

Company: Protalix Biotherapeutics (PLX)
Drug/indication: prGCD for Gaucher's disease
Clinical trial event: Phase III results
Timing: Fourth quarter

Protalix says it will seek FDA approval for prGCD if results are positive from this pivotal phase III study. The drug, if approved, would compete against Genzyme's Cerezyme.

Company: Repros Therapeutics (RPRX)
Drug/indication: Proellex for uterine fibroids
Clinical trial event: Phase III results
Timing: Fourth quarter

This is the first of two phase III studies required for Repros to seek regulatory approval of Proellex. Results from the second study are expected early next year.

Company: Vertex Pharmaceuticals (VRTX - Get Report)
Drug/indication: Telaprevir for hepatitis C
Clinical trial event: Phase II twice-daily dosing data
Timing: 2009

Vertex will release final data from a phase II study investigating whether telaprevir can be dosed twice daily instead of three times daily.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
ONXX $0.00 0.00%
CELG $110.55 0.00%
INSM $21.20 0.00%
JAZZ $180.74 0.00%
MYGN $34.18 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs